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Objectives. This work was done to determine the role of 
hypertension treatment in the prevention of disease progression, 
left ventricular hypertrophy and congestive heart failure. 
Background. Lowering of blood pressure in hypertensive pa- 
tients has been reported to reduce morbidity and mortality from 
strokes and myocardial infarction. Data on primary prevention of 
disease progression, left ventricular hypertrophy and congestive 
heart failure have not previously been carefully quantified. 
Methods. All the major long-term hypertension treatment rials 
over the past 20 years were reviewed. 
Results. One thousand four hundred ninety-three of 13,342 
subjects in the control groups compared with only 95 of 13,389 in 
the treated groups progressed from less severe to severe hyper- 
tension. The incidence of left ventricular hypertrophy in treated 
compared with control or placebo subjects was 140 of 6,150 and 
216 of 6,098 subjects, respectively; congestive heart failure oc- 
curred in 240 of 6,923 subjects in the control group compared with 
only 112 of 6,914 treated subjects. 
Conclusions. The lowering of blood pressure over a 3- to 5-year 
period of time is effective in preventing severe disease, left 
ventricular hypertrophy and congestive heart failure in addition 
to strokes and myocardial infarction. In an era when expensive 
and often complicated methods are being used to prevent recur- 
rence of congestive heart failure or myocardial infarction, it is 
important to highlight the role of antihypertensive therapy in 
primary prevention. 
(J Am CoU Cardiol 1996;27:1214-8) 
Before the 1950s, approximately 40% of deaths from hyper- 
tension resulted from congestive heart failure (1,2). This trend 
was reversed with the introduction of effective antihypertensive 
drugs in the 1950s and 1960s and the lowering of blood 
pressure in large numbers of hypertensive patients. A recent 
review concluded that the occurrence of heart failure in 
hypertensive subjects had been dramatically reduced in 
younger persons and that congestive heart failure onset was 
delayed by several decades; at present it occurs primarily as a 
complication of coronary artery disease (3). 
Data on the primary prevention of left ventricular hyper- 
trophy and congestive heart failure have not always been 
specifically quantified in the major hypertension treatment 
trials. Analyses have tended to focus on so-called "hard end 
points" in estimating benefits of treatment--the incidence of 
strokes and stroke deaths, myocardial infarctions and deaths 
from myocardial infarction (4,5). Prevention of progression 
from less to more severe hypertensive disease and the preven- 
tion of left ventricular hypertrophy and congestive heart failure 
From the Section of Preventive Cardiology, Yale University. School of 
Medicine, New Haven, Connecticut; and *Division of Preventive Medicine, 
Brigham and Women's Hospital, Harvard Medical School, Boston, Massachu- 
setts. This work was supported by grants from the Westchester County, New 
York Hypertension Foundation and the Boehringer Mannheim Pharmaceutical 
Co., Mannheim, Germany. 
Manuscript received May 26, 1995; revised manuscript received Novem- 
ber 30, 1995, accepted December 6, 1995. 
Address for corresoondence: Dr. Marvin Moser, 13 Murray Hill Road, 
Scarsdale, New York 10583. 
or reversal of pretreatment left ventricular hypertrophy have 
not, therefore, often been factored into the benefit equation. 
For these reasons, most analyses of the clinical trials tend to 
underestimate b nefit of treatment (6). 
Diuretics were used as initial monotherapy or in combina- 
tion with reserpine, hydralazine or methyldopa in almost all of 
the clinical trials in the 1960s to 1980s (7-13). One early study 
compared iuretics to beta-adrenergic blocking drugs (14). In 
the past 15 years, several large-scale studies have used either 
diuretics or beta-blockers as initial therapy or compared 
diuretics to beta-blockers (15-20). 
Methods  
In a previous metaanalysis of hypertension treatment re- 
suits (4), we summarized ata on coronary heart disease and 
stroke end points. 
Review of clinical trends, For this overview e reviewed all 
of the major clinical trials listed in Table 1 to determine the 
numbers of subjects who progressed from less severe (stage I
or II) to more severe hypertension, the degree to which the 
incidence of congestive heart failure was reduced in treated 
compared to control or placebo subjects and, where possible, 
the degree to which left ventricular hypertrophy was pre- 
vented. 
There were no other long-term trials (more than 6 months 
in duration) that we were able to identify that contain placebo 
or control groups or sufficient numbers of subjects (more than 
25) to warrant inclusion in our analysis. In addition, the initial 
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Table 1. Congestive Heart Failure Reported in Randomized Trials 
of Blood Pressure Lowering* 
Active Treatment Control Treatment 
Congestive Congestive 
Study Heart No. Heart No. 
(ref no.) Failure Randomized Failure Randomized 
Osto (12) 0 406 1 379 
VA I (7) 0 68 4 63 
VAII (8) 0 186 11 i94 
Australian National Blood 3 1,721 3 1,706 
Pressure Study 
(ANBPS) (11) 
U.S. Public Health Service 0 193 2 196 
(USPHS) (9) 
Systolic Hypertension i  56 2,365 109 2,371 
the Elderly (SHEP) (19) 
STOP-Hypertension (15) 19 812 39 815 
EWPHE (18) 7 416 17 424 
Coope (20) 22 419 36 465 
HSCSG (13) 0 233 6 219 
Wolf (28) 2 45 8 42 
Carter (29) 3 50 4 49 
Total: all trials 112 6,914 240 6,923 
*Not recorded in Hypertension Detection and Follow-up Program (10,11), 
Medical Research Council Trial of Mild Hypertension (14) and Medical 
Research Council Trial of Treatment of Hypertension i  Older Adults (17). 
Active treatment versus control treatment: relative risk 0.48 (95% confidence 
interval 0.38 to 0.59). EWPHE = European Working Party on High Blood 
Pressure in the Elderly; HSCSG = Hypertension-Stroke Cooperative Study 
Group; STOP-Hypertension - Swedish Trial in Old Patients With Hyperten- 
sion; VA - Veterans Administration. 
Medical Research Council (MRC) trial (14) and the MRC trial 
in the elderly (17) were omitted from this part of our analysis 
because neither provided ata on the development of conges- 
tive heart failure or left ventricular hypertrophy. The trials 
reviewed differed greatly in size and characteristics of the 
population studied, but all of them used diuretics either as 
initial monotherapy or as one of the two first-step treatments. 
At the time most of these trials were initiated, angiotensin- 
converting enzyme inhibitors and calcium channel blockers 
were not available. The majority of subjects in the larger trials 
were stage I or stage II hypertensives, although in the Veterans 
Administration and the HDFP trials, there were individuals 
with more severe degrees of hypertension. Several trials spe- 
cifically examined the effects of treatment in the elderly, that is, 
the European Working Party Study (18), Coope and Warren- 
der (20), the Systolic Hypertension i  the Elderly (SHEP) (19) 
and the Swedish Trial in Old Persons (STOP-Hypertension) 
(15). The Australian and HDFP trials also had cohorts of 
elderly patients (10,11). In hypertension treatment s udies of 
the elderly, benefit of treatment (or lack of it) was easier to 
demonstrate b cause of the larger numbers of vascular events 
that occurred over a reasonably short period of time (3 to 5 
years) in both treated and control subjects. 
Methods of analysis. Data on congestive heart failure and 
left ventricular hypertrophy were analyzed as follows. We used 
standard methods for combining information from 2 × 2 tables 
to perform the statistical overview (21). We calculated typical 
odds ratios (which approximate the relative risk, RR) for the 
incidence of congestive heart failure and left ventricular hy- 
pertrophy and calculated 95% confidence intervals. The spe- 
cific formulas for these risk estimates and the test for statistical 
significance have been described elsewhere (21). 
Resu l ts  
Prevention of congestive heart failure. In the original 
Veterans Administration study of severe hypertensives (7) 
(with pretreatment diastolic pressures of 115 to 129 mm Hg), 
there were four cases of congestive heart failure in the 
nontreated group versus none in the treated group (Table 1). 
These patients received triple drug therapy (diuretics, reser- 
pine and hydralazine). In other relatively small studies of 
patients from the Veterans Administration with moderately 
severe hypertension (8), 6% to 9% of patients had entered the 
study with a history of congestive heart failure before random- 
ization. Eleven of 194 patients developed congestive heart 
failure in the control group, whereas none in the treated group 
of 186 developed this complication. Nine of the 11 patients 
who developed congestive heart failure were over 60 years of 
age. In the U.S. Public Health Service Study (9), two patients 
in the placebo group developed congestive heart failure com- 
pared to none in the group treated with a diuretic and 
reserpine. The Australian Trial in Mild Hypertension (11) 
studied a much larger group of subjects with less severe 
hypertension a d little evidence of pretreatment target organ 
involvement. The probability of an occurrence of a cardiovas- 
cular event was low. Even in a study of this size, with more than 
3,000 subjects, it is difficult o demonstrate statistically signif- 
icant benefits of therapy with a low risk population. There was 
actually no difference between the small percentage ofpatients 
who developed congestive heart failure in the treated com- 
pared to the placebo subjects (3 of 1,721 versus 3 of 1,706). In 
the HDFP study (10), we were unable to find the numbers of 
subjects who developed congestive heart failure. 
The HAPPHY study (16) compared a diuretic to a beta- 
blocker but did not include a control or placebo group. A 
congestive heart failure incidence was reported of 1.8 per 1,000 
patient years in the diuretic group and 2.6 per 1,000 patient 
years in the beta-blocker cohort. These data suggest an in- 
creased benefit in the subjects treated with a diuretic, but the 
difference was not statistically significant. These findings are 
not included in the present metaanalysis. 
Congestive heart failure results in the elderly. Much of the 
data on the reduction in congestive heart failure comes from 
the studies of elderly hypertensives. In the SHEP study (19), 
treatment included a small dose of a diuretic with a beta- 
blocker added if blood pressures were not reduced to goat 
levels. A high percentage of subjects achieved goal blood 
pressures on diuretic monotherapy. Congestive heart failure 
occurred in 56 of 2,365 people in the active treatment group 
compared to 109 of 2,371 people in the control or placebo 
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Table 2. Left Ventricular Hypertrophy Reported in Randomized Trials of Blood 
Pressure Lowering* 
Active Treatment Control Treatment 
Left Left 
Ventricular No. Ventricular No. 
Hypertrophy Randomized Hypertrophy Randomized 
Oslo (12) 0 406 7 379 
U.8. Public Health Service (USPHS) (9) 13 193 25 196 
EWPHE (18) 0 416 1 424 
Hypertension Detection and Follow-up 127 5,135 183 5,099 
Program (HDFP) (22) 
Total: all trials 140 6,150 216 6,098 
*Not recorded in 11 other trials reviewed. Relative risk 0.65 for treated versus control (95% confidence interval 0.52 
to 0.79). EWPHE = European Working Party on High Blood Pressure in the Elderly. 
group. There was a reduction of more than 50% in congestive 
heart failure incidence. In the EWPHE study (18), which also 
was diuretic based, there was a reduction of 63% in the 
incidence of congestive heart failure (7 of 416 or 5 per 1,000 
patient years in the treated compared to 17 of 424 or 13 per 
1,000 patient years). Coope and Warrender (20) reported a
decrease of 33% (22 of 419 in the treated group compared to 
36 of 465 in the control group). The STOP-Hypertension study 
(15) reported 39 patients who developed congestive heart 
failure in the placebo group compared to 19 in the treated 
group, a reduction of 51%. This trial compared several differ- 
ent beta-blockers to a diuretic as well as a placebo. There are 
no data available on the specific incidence of congestive heart 
failure with different medications. 
When all of the studies are combined, a large and statisti- 
cally significant reduction of 52% was found in the occurrence 
of congestive heart failure in the hypertension treatment trials 
in treated compared to control or placebo subjects (relative 
risk [RR] 0.48, 95% confidence interval [CI] 0.38 to 0.59). As 
noted, most of these trials used diuretics as initial therapy. 
Overall, 112 individuals assigned to active treatment devel- 
oped congestive heart failure compared to 240 in the control 
group. The numbers of events that occurred in the treated and 
comparison groups and the relative risk estimates are shown in 
Table 1. Data on the incidence of congestive heart failure were 
available in 12 of the 15 trials reviewed. 
Prevention of left ventrieular hypertrophy. Data were 
available in only four of the trials reviewed (Table 2). 
In the HDFP study, new onset left ventricular hypertrophy 
by ECG criteria developed in only 127 subjects treated in the 
stepped-care (SC) or special treatment groups compared to 
183 in the RC (regular care) group (22). (This trial was not 
placebo controlled; patients in the RC group were treated with 
some blood pressure-lowering medication. Difference between 
groups may have actually been greater had one group received 
a placebo). Left ventricular hypertrophy was present in almost 
45% of subjects in both the SC and the RC groups at baseline. 
Medication in the HDFP study included the use of chlorthali- 
done, 25 to 100 mg with or without a potassium-sparing a ent, 
reserpine, 0.1 to 0.25 mg, or methyldopa and hydralazine, 30 to 
200 mg/day when necessary. 
Overall, a total of 140 subjects developed left ventricular 
hypertrophy in the treated compared to 216 in the control or 
placebo cohorts. For left ventricular hypertrophy, the RR was 
0.650 (a reduction of 35%) and also statistically significant 
(95% CI 0.52 to 0.79). 
Prevention of progression of less severe to more severe 
hypertension. Table 3 summarizes data available from the 
clinical trials on the numbers of patients who progressed from 
less to more severe hypertension, defined as blood pressure 
readings of >200/>110 mm Hg. Only 95 of 13,389 patients in 
the treated group progressed compared to 1,493 of 13,342 
patients in the control or placebo groups. 
Discuss ion  
In a previous metaanalysis of 17 of the long-term hypertension 
treatment trials, we reported a statistically sign!ficant reduction of 
38% in stroke mortality and 16% in coronary heart disease 
mortality (4). We had also previously reported a marked ecrease 
in the number of patients reported to progress from less severe to 
severe hypertension i  treated compared to Control subjects (6). 
The present review concerns itself with an update on numbers of 
subjects who progressed from less severe to more severe degrees 
Table 3. Effect of Treatment on Preventing Progression From Less 
or Moderately Severe to More Severe Hypertension 
Study 
Placebo Active Treatment 
Progressed Progressed 
to More to More 
No. Severe* No. Severe* 
USPHS (9) 196 241" 193 0 
VA Cooperative (7) 194 20 186 0 
Australian (11) 1,706 198 1,721 5 
Oslo (12) 379 65 406 1 
MRC (14) 8,654 1,011 8,700 76 
MRC-Elderty (17) 2,213 175 2,183 13 
Total 13,342 1,493 13,389 95 
*Diastolic blood pressure >110 mm Hg, systolic blood pressure >200 to 
210 mm Hg. ?Diastolic blood pressure >130 mm Hg. From data available from 
the clinical trials. Abbreviations a  in Table 1. 
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of hypertension, the prevention of left ventricular hypertrophy 
and the primary prevention of congestive heart failure. These 
data provide additional evidence of benefit from the treatment of
hypertension. 
When all of the hypertension treatment trials are reviewed, 
a marked reduction i  the numbers of subjects who progressed 
to severe hypertension i treated compared to control or 
placebo subjects is noted. In addition, a large and highly 
significant decrease of 35% and 52%, respectively, was found 
in the occurrence of left ventricular hypertrophy and in the 
incidence of congestive heart failure in treated compared to 
control or placebo patients. These results should be factored 
into any "benefit of treatment" analysis. Pooling of data in a 
review of this type may pose difficulties if there are negative or 
equivocal studies that are combined with more positive ones. 
However, in this analysis of progression to more severe 
disease, left ventricular hypertrophy and congestive heart 
failure, data are highly consistent in all studies and all popu- 
lation groups (except for the lack of difference in the Austra- 
lian Trial in Mild Hypertension) despite differences in demo- 
graphic characteristics and possible differences in criteria for 
the diagnosis of congestive heart failure. Statistical errors are 
much less likely to occur in studies where results all move in 
the same direction. 
Regression of left ventricnlar hypertrophy. This is another 
factor that should also be considered in estimating benefit of 
treatment ofhypertension. It is well known that the treatment 
of hypertension will cause regression of both left ventricular 
mass and wall thickness. The long-term use of any of the 
available ffective antihypertensive drugs, with the exception of 
the direct vasodilators, will result in regression of left ventric- 
ular hypertrophy (23). A recent metaanalysis suggested that 
angiotensin-converting e zyme inhibitors were most effective 
in causing regression, with diuretics, beta-blockers and calcium 
antagonists omewhat less effective. However, many of the 
studies included in this metaanalysis were of short duration or 
included small numbers of subjects (24). In two recent placebo- 
controlled studies (25,26), left ventricle mass and wall thick- 
ness decreased to the greatest extent with diuretics when 
compared with other classes of drugs, including angiotensin- 
converting enzyme inhibitors, beta-blockers, alpha-blockers 
and calcium channel blockers. In the diuretic-based SHEP 
study (19), a statistically significant reduction in left ventricle 
mass was noted in treated compared to placebo subjects. In 
addition, in many other long-term trials, either ECG or 
echocardiographic evidence of regression of left ventricular 
hypertrophy as been reported to occur more often in treated 
than in placebo r control subjects. It is reasonable toassume 
that he regression of left ventricular hypertrophy is largely the 
result of blood pressure reduction, although some investigators 
believe that other factors may be of importance (27). Despite 
concerns that the decrease in left ventricular muscle mass 
might be deleterious, cardiac function is not adversely affected 
in patients whose left ventricular hypertrophy has regressed. 
Because left ventricular hypertrophy most often precedes 
congestive heart failure in hypertensive individuals, the pre- 
vention of left ventricular hypertrophy or a decrease in left 
ventricle muscle mass as well as wall stress in subjects with 
pretreatment left ventricular hypertrophy is most probably the 
major reason for the decrease in the occurrence of congestive 
heart failure with blood pressure lowering. As noted in the 
treatment trials from which data were available, there was a 
highly significant decrease of 35% in the occurrence of left 
ventricular hypertrophy in treated compared to control or 
placebo subjects. 
Effects of specific medications on prevention of congestive 
heart failure. It is clear that the treatment of hypertension, 
primarily with diuretics alone or in combination with antiad- 
renergic agents including beta-adrenergic inhibitors, results in 
the primary prevention of congestive heart failure; congestive 
heart failure is rare in hypertensive individuals whose blood 
pressures have been well controlled and who have not sus- 
tained a myocardial infarction. None of the long-term trials 
used other antihypertensive agents. Although it is possible that 
similar esults will be obtained with the angiotensin-converting 
enzyme inhibitors or calcium channel blockers, we must await 
the results of several ongoing studies before we can conclude 
that equivalent results can be obtained with these medications. 
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